Twist Bioscience Current Ratio 2017-2021 | TWST

Current and historical current ratio for Twist Bioscience (TWST) from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Twist Bioscience current ratio for the three months ending June 30, 2021 was 10.52.
Twist Bioscience Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.58B $0.06B 10.52
2021-03-31 $0.61B $0.04B 15.03
2020-12-31 $0.63B $0.04B 17.10
2020-09-30 $0.34B $0.04B 9.29
2020-06-30 $0.35B $0.03B 10.98
2020-03-31 $0.26B $0.03B 8.61
2019-12-31 $0.13B $0.06B 2.24
2019-09-30 $0.16B $0.03B 5.28
2019-06-30 $0.18B $0.03B 7.18
2019-03-31 $0.12B $0.02B 6.51
2018-12-31 $0.15B $0.02B 7.72
2018-09-30 $0.10B $0.02B 5.16
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.07B $0.01B 7.16
2016-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.960B $0.090B
Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71